Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $35.1252W HIGH $64.16
Volume
9.65 M
Value Traded
481.64 M
Short % Float
0.79%
+2.93%Week
-12.2%1 Month
-21.59%3 Month
+1.74%6 Month
+10.33%5 Year
+28,000%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
172.53 B
EPS (TTM)
4.27
P/E Ratio
9.06
Ent. Value
218.18 B
Total Shares
4.46 B
Float Shares
3.35 B
Insiders
0.01%
Institutions
9.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NVO Catalyst Timeline
Dated clinical, regulatory and corporate events for Novo Nordisk A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novo Nordisk A/S
82Total events
10Upcoming
35Tier-1 (high impact)
2025 to 2029Coverage
Upcoming catalysts 2
Event history 50
▼Timing GuidanceDenecimigFiledPresentation
FDA informed Novo denecimig BLA review is still ongoing with no new timeline for regulatory action
haemophilia Asource ↗
▼Approval Delay AnnouncedDenecimigFiledFDA Decision
FDA informed Novo that denecimig BLA review is extended due to ongoing facility remediation activities
haemophilia Asource ↗
●Quarterly UpdateCorporate
Weekly share repurchase transactions reported (28 September – 2 October 2026)
▲Additional DataSemaglutideApprovedClinical Data
Post hoc analysis of STEP UP sub-population shows semaglutide reduced liver fat to normal levels in 9 of 10 adults
Obesity with excess liver fatsource ↗
▲Oral PresentationSemaglutideApprovedPresentation
STEP UP pooled liver analysis presented at EASD Annual Meeting 2026
Obesity with excess liver fatsource ↗
▲Topline ReadoutCagriSemaFiledClinical Data
REIMAGINE 1 MRI sub-study data presented at EASD 2026 showing reductions in abdominal, liver and pancreas fat with 14.3% weight reduction at week 40
Early type 2 diabetessource ↗
●Quarterly UpdateCorporate
Cumulative repurchases since 4 February 2026 total 35,379,179 B shares
▲Partnership / LicenseCorporate
Orbis Medicines enters multi-target drug discovery partnership with Novo Nordisk worth up to USD 1.4 billion
cardiometabolic diseasessource ↗
▲CHMP Positive OpinionDenecimigFiledEx-US Regulatory
Denecimig received a positive CHMP opinion
haemophilia Asource ↗
▲Primary Endpoint MetSemaglutideApprovedClinical Data
STEP Young phase 3 met primary endpoint of BMI reduction at week 68
obesity in children aged 6 to under 12 yearssource ↗
▲Topline ReadoutSemaglutideApprovedClinical Data
First results from STEP Young phase 3 trial announced
obesity in children aged 6 to under 12 yearssource ↗
▲Partnership / LicenseCorporate
Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI
▲IP Litigation RulingSemaglutideApprovedIP / Competition
Dutch court grants preliminary injunction against Ceban for infringing semaglutide SPC
▲Partnership / LicenseCorporate
H1 partners with Novo Nordisk to scale AI-driven clinical development
▼Primary Endpoint MissedZiltivekimabClinical Data
ZEUS phase 3 trial with ziltivekimab did not meet primary endpoint
cardiovascular diseasesource ↗
▼Quarterly UpdateMonlunabantDiscontinuedCorporate
Non-cash impairment charge of DKK 4.0 billion related to monlunabant
▼Program DiscontinuationMonlunabantDiscontinuedCorporate
Impairment charge related to monlunabant
▼Topline ReadoutZiltivekimabClinical Data
ZEUS topline results announced: MACE risk reduction not met
atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammationsource ↗
▼Primary Endpoint MissedZiltivekimabClinical Data
ZEUS primary endpoint missed: no MACE benefit
atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammationsource ↗
◆IP Litigation RulingIP / Competition
Novo Nordisk files lawsuit against Eli Lilly for false advertising of Zepbound and Mounjaro
▲Full ResultsWegovyApprovedClinical Data
STEP UP trial results for Wegovy 7.2 mg showing ~19% weight loss
obesitysource ↗
▲Product LaunchKyinsu®Post-Market
Launch of Kyinsu® on Fangzhou's Internet hospital platform in China
type 2 diabetessource ↗
▲EU ApprovalWegovy®pillApprovedEx-US Regulatory
EC approval of Wegovy pill for weight management
obesity and overweightsource ↗
▲Oral PresentationDenecimigFiledPresentation
Interim FRONTIER4 data presented at ISTH 2026
hemophilia Asource ↗
▲Poster PresentationDenecimigFiledPresentation
Patient-reported outcomes from FRONTIER4 presented at ISTH 2026
hemophilia Asource ↗
▲Oral PresentationConcizumabApprovedPresentation
First-time explorer10 data presented at ISTH 2026
hemophilia A or B with inhibitorssource ↗
▲Product LaunchWegovy®pillApprovedPost-Market
Launch of Wegovy pill in more countries in 2H 2026
obesity and overweightsource ↗
◆Timing GuidanceDenecimigFiledPresentation
Anticipated FDA regulatory decision for denecimig BLA in Q3 2026
haemophilia Asource ↗
▲MHRA MilestoneWegovy®pillApprovedEx-US Regulatory
MHRA approval of Wegovy®pill (semaglutide tablets) for weight management in the UK
obesity or overweight with weight-related conditionsource ↗
▲Full ResultsSemaglutideApprovedClinical Data
OASIS 4 topline results: semaglutide tablets 25 mg achieved ~14% weight loss vs ~2% placebo (treatment policy) and ~17% vs ~3% (on-treatment) at 64 weeks
obesity or overweight with weight-related condition without diabetessource ↗
▲Product LaunchWegovy®pillApprovedPost-Market
Anticipated availability of Wegovy®pill via private prescription in the UK within weeks
obesity or overweight with weight-related conditionsource ↗
◆Oral PresentationSemaglutideApprovedPresentation
ESSENCE Menopause subgroup analysis presented at EASL 2026
MASHsource ↗
◆Oral PresentationPresentation
POSEIDON study results presented at EAS Congress
cardiovascular diseasesource ↗
▲CHMP Positive OpinionEx-US Regulatory
CHMP recommends EU approval of Wegovy 7.2 mg single-dose pen
obesitysource ↗
▲CHMP Positive OpinionWegovy®pillApprovedEx-US Regulatory
CHMP positive opinion recommending marketing authorisation of Wegovy®pill for weight management in the EU
obesity or overweight with comorbiditiessource ↗
●Timing GuidancePresentation
Novo Nordisk initiated share repurchase programme under Safe Harbour Rules
●Corporate ApprovalCorporate
Novo Nordisk initiates share repurchase programme under Safe Harbour Rules
▼Equity OfferingCorporate
Novo Nordisk initiates share repurchase programme of up to DKK 11.2 billion
Past FDA Catalysts and PDUFA Decisions
How NVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-11 | concizumab (Alhemo) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A88 / 100
Pipeline Score
$154.1B
Pipeline Value
$200.3B
Commercial Value
Undervalued
Valuation Signal
92
Drugs Scored
3.0x
rNPV / MCap
Top 1%
Large Pharma(rank 1 of 660)
Percentile Rank
Novo Nordisk A/S earns an A-grade pipeline score (88/100), with $154.2B risk-adjusted pipeline value, led by Faster-acting insulin aspart in Diabetes (Phase 3).
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from DKK to USD, to Dec 2025; product lines from the latest annual filing) Revenue $46.8B x 4.3 = $200.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Ozempic | $19.2B | $18.2B | +5.6% |
| Wegovy | $12.0B | $8.8B | +35.9% |
| Rybelsus | $3.3B | $3.5B | -5.2% |
| NovoRapid And NovoLog | $2.4B | $2.5B | -5.3% |
| Tresiba | $1.8B | $1.5B | +21.6% |
| NovoSeven | $1.1B | $1.2B | -8.2% |
| Ryzodeg | $815M | $746M | +9.2% |
| NovoMix And NovoLog Mix | $747M | $887M | -15.8% |
| Xultophy | $699M | $682M | +2.6% |
| Saxenda | $491M | $1.1B | -53.3% |
| Victoza | $457M | $830M | -44.9% |
| Fiasp | $427M | $283M | +50.8% |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cagrilintide Small moleculeNCT05567796 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 6,004 | Oct 19, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CagriSema | obesity and type 2 diabetes | Phase 3a | 2026-09-30 | 22.4% reduction in body weight versus placebo at 52 weeks; 14.3% body-weight reduction at week 40; 14.2% body-weight reduction with CagriSema at week 68Read More | Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health · EASD 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.1 % (-26.7 %) | 28.76 M | 600.00 K | 50% ( 200.00 K) |
NVO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVO ranks across every disease it competes in
Competitive Position is a premium feature
See how NVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVO News
NVONovo Nordisk A/S – Share repurchase programme
Novo Nordisk has initiated a share repurchase program on May 6, 2026, as part of a larger initiative to buy back shares worth up to DKK 15 billion over 12 months. As of October 2, 2026, the company has repurchased 36,604,179 B shares, totaling approximately DKK 10.25 billion. This move is aimed at enhancing shareholder value and reflects the company's strong market position.
Read more →NVONovo provides update on the denecimig Biologics License Application (BLA) in the US
Novo Nordisk announced that the FDA's review of the Biologics License Application for denecimig, a treatment for haemophilia A, is ongoing. The FDA has not identified any deficiencies in the clinical data but has extended the review due to facility remediation activities. Novo aims to launch denecimig in the US in the first half of 2027, despite the delays.
Read more →NVONovo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
Novo Nordisk reported that its drug Wegovy® (semaglutide) significantly reduced liver fat in adults with obesity. In a sub-population analysis from the STEP UP trial, 88.5% of participants with elevated liver fat achieved normal levels after 72 weeks of treatment. The average liver fat percentage decreased from 8.8% to 3.1%, indicating improved liver health.
Read more →NVONovo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
Novo Nordisk presented promising new data on CagriSema at the EASD Annual Meeting 2026. The investigational drug demonstrated significant effects on reducing cravings and improving eating behavior in individuals with obesity. Additionally, it showed beneficial impacts on abdominal fat and bone health in adults with type 2 diabetes. These findings suggest CagriSema may address underlying factors of obesity and diabetes beyond weight loss.
Read more →NVONovo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Novo Nordisk has entered an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist. The deal is valued at up to $2.6 billion, including a $300 million upfront payment. HRS-1596 aims to offer once-weekly oral dosing, potentially enhancing treatment convenience for obesity and type 2 diabetes. The agreement excludes certain regions in Asia and is subject to regulatory approvals.
Read more →NVONovo Nordisk A/S - share repurchase programme
Novo Nordisk has initiated a share repurchase program aimed at buying back B shares worth up to DKK 15 billion over a 12-month period. As of September 25, 2026, the company has already repurchased 35,379,179 B shares at an average price of DKK 280.95. This initiative reflects the company's commitment to enhancing shareholder value.
Read more →NVONovo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Novo Nordisk announced positive topline results from the phase 3 REIMAGINE 5 trial, showing that CagriSema (cagrilintide and semaglutide) achieved a superior average weight loss of 12.4% compared to tirzepatide's 9.1%. Additionally, CagriSema demonstrated non-inferior HbA1c reduction. The findings suggest strong potential for CagriSema in treating obesity and type 2 diabetes, with further data expected on diabetic neuropathy.
Read more →NVONovo and UNICEF expand partnership to support a healthier start for more than 80 million children
Novo Nordisk and UNICEF have announced a four-year expansion of their partnership to combat childhood obesity, targeting over 80 million children in seven countries. The initiative will focus on creating healthier environments and promoting better nutrition and physical activity. Novo is investing $18 million from 2026 to 2030 to support this program, which aims to implement evidence-based policies and interventions.
Read more →NVO▼ -8%on this newsshared move
Highlights to be presented at Novo’s Capital Markets Day 2026
Novo Nordisk is hosting its Capital Markets Day in London, outlining its corporate strategy and ambitions for 2030. Key highlights include plans to launch more than five multi-blockbuster drugs and to serve over 60 million patients globally. The company aims for sustainable growth and attractive returns while maintaining a stable operating margin.
Read more →NVONovo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
Novo Nordisk's Sogroya® (somapacitan) has received a positive opinion from the CHMP for treating idiopathic short stature (ISS) in children. This would mark the first approved growth hormone therapy for ISS in the EU, addressing a significant unmet need. The recommendation follows previous approvals for other conditions, with a decision from the European Commission expected later this year.
Read more →NVONovo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
Novo Nordisk's FREHEMGO® (denecimig) has received a positive recommendation from the CHMP for EU approval to treat haemophilia A in both adults and children. This innovative treatment offers flexible dosing options and has shown significant efficacy in clinical trials, reducing annualized bleeding rates. The company plans to launch FREHEMGO® in Europe starting in late 2026.
Read more →NVOOrbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
Orbis Medicines has entered a strategic partnership with Novo Nordisk to develop oral macrocycle therapeutics targeting cardiometabolic diseases. This collaboration allows for the acceleration of creating a new class of medicines. The agreement could yield up to USD 1.4 billion, reflecting significant investment in innovative therapies.
Read more →NVONovo and Anthropic will collaborate to advance drug discovery with Claude
Novo Nordisk has announced a collaboration with Anthropic to enhance drug discovery through AI. The partnership aims to address specific scientific challenges and improve R&D productivity. By utilizing Anthropic's models, Novo seeks to accelerate the development of new medicines and strengthen AI-driven software development. The collaboration emphasizes responsible AI application and data governance.
Read more →NVONovo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
Novo Nordisk will present new data at the EASD 2026 meeting, showcasing advancements in their cardiometabolic portfolio, including insights on the Wegovy® pill and CagriSema. The data covers various conditions such as obesity, type 2 diabetes, and cardiovascular diseases. Key presentations will include real-world evidence and innovative findings on appetite regulation and body composition.
Read more →NVONovo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
Novo Nordisk has launched a rebranding initiative centered on the theme 'Lasting Health Starts Now' and introduced a new corporate culture called 'The Novo Way'. This rebrand aims to enhance engagement with stakeholders and improve health accessibility. The company emphasizes its commitment to innovation and patient safety while preparing for a competitive market landscape.
Read more →NVONovo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
Novo Nordisk announced positive results from the STEP Young phase 3 trial, where 40.4% of children aged 6 to under 12 treated with semaglutide achieved a BMI below the obesity threshold after 68 weeks. The trial demonstrated significant BMI reduction compared to placebo, with both groups receiving lifestyle modifications. The safety and tolerability of semaglutide were consistent with previous trials.
Read more →About Novo Nordisk A/S
BIOPHARMAWATCH ELITE PLUS
Trade the next NVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime